Analystreport

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at JPMorgan Chase & Co. from $39.00 to $40.00. They now have an "overweight" rating on the stock.

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares  (KNSA) 
Last kiniksa pharmaceuticals, ltd. - class a ordinary shares earnings: 8/12 04:02 pm Check Earnings Report